Article content material
VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) — Aequus Prescription drugs Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Firm”), is happy to announce that Well being Canada has authorised Zimed® PF (Bimatoprost 0.03%) for the discount of elevated intraocular stress (IOP) in sufferers with open-angled glaucoma or ocular hypertension. Affecting greater than 700,000 folks in Canada, glaucoma is without doubt one of the main causes of blindness in North America.
Zimed® PF is the primary prostaglandin analog (PGA) that’s preservative free and supplied in an easy-to-use multi-dose bottle in Canada. PGAs are generally prescribed first-line to scale back IOP. The overwhelming majority of medicines at present out there embrace preservatives akin to Benzalkonium Chloride (BAK). Power publicity to BAK has been discovered to extend the probability of experiencing Ocular Floor Illness (OSD) and scale back affected person adherence.
Article content material
“Now we have heard from the eyecare professionals that there’s a want for preservative-free options,” says Grant Larsen, CCO of Aequus Pharma. “The PGA market continues to develop year-over-year and we’re excited to offer a brand new choice for Canadian well being care suppliers and their sufferers.”
Zimed PF is contained in a singular multi-dose bottle that leverages a unidirectional valve and air filter expertise to eliminates the necessity for a preservatives. As well as, this packaging format considerably reduces the quantity of plastic used in comparison with single-use options.
“Medicom is worked up by this information and appears ahead to launching Zimed® PF within the Canadian market with Aequus,” says Simon Martin, CEO of Medicom. “Globally we now have seen the robust uptake for Zimed® PF and happy it’ll quickly be out there to Canadian sufferers.”
Article content material
Doug Janzen, CEO of Aequus Pharma mentioned, “We wish to thank Medicom for his or her help by way of the approval course of with Well being Canada. That is our third product we’ve dropped at Canada on this partnership. We stay up for launching Zimed® PF in 2023 and offering Canadians with extra remedy choices.”
ABOUT AEQUUS PHARMACEUTICALS INC.
Aequus Prescription drugs Inc. (TSX-V: AQS, OTCQB:
AQSZF) is a specialty pharmaceutical firm centered on growing and commercializing top quality, differentiated merchandise. Aequus has grown its gross sales and advertising and marketing efforts to incorporate a number of industrial merchandise in ophthalmology and optometry. Aequus plans to construct on its Canadian industrial platform by way of the launch of extra merchandise which are both created internally or introduced in by way of an acquisition or license, remaining centered on extremely specialised therapeutic areas. For additional info, please go to
www.aequuspharma.ca.
Article content material
FORWARD-LOOKING STATEMENT DISCLAIMER
This launch could include forward-looking statements or forward-looking info beneath relevant Canadian securities laws (collectively, “forward-looking statements”) that will not be primarily based on historic truth, together with, with out limitation, statements containing the phrases “imagine”, “could”, “plan”, “will”, “estimate”, “proceed”, “anticipate”, “intend”, “count on”, “potential” and related expressions. Ahead- trying statements are essentially primarily based on estimates and assumptions made by us in mild of our expertise and notion of historic developments, present situations and anticipated future developments, in addition to the elements we imagine are applicable. Ahead-looking statements used herein embrace however usually are not restricted to statements referring to: the implementation of our enterprise mannequin and strategic plans; launch and entry to insurance coverage reimbursement for Zimed® PF and anticipated timing contemplated herein, if in any respect; anticipated or projected development developments and entry to authorities reimbursement, by province into the long run; and the Firm’s capacity to safe potential companions to additional develop our product portfolio. Such statements replicate our present views with respect to future occasions and are topic to dangers and uncertainties and are essentially primarily based upon quite a lot of estimates and assumptions that, whereas thought-about cheap by Aequus, are inherently topic to vital enterprise, financial, aggressive, political and social uncertainties and contingencies. Many elements might trigger our precise outcomes, efficiency, or achievements to be materially completely different from any future outcomes, efficiency, or achievements which may be expressed or implied by such forward-looking statements. In making the ahead trying statements included on this launch, the Firm has made numerous materials assumptions, together with, however not restricted to: acquiring regulatory approvals; basic enterprise and financial situations; the Firm’s capacity to efficiently out license or promote its present merchandise and in-license new merchandise; the idea that the Firm’s present good relationships with third events might be maintained; the provision of financing on cheap phrases; the Firm’s capacity to draw and retain expert workers; market competitors; the merchandise and expertise supplied by the Firm’s opponents; the influence of the coronavirus (COVID-19) on the Firm’s operations; and the Firm’s capacity to guard patents and proprietary rights. In evaluating ahead trying statements, present and potential shareholders ought to particularly contemplate numerous elements set out herein and beneath the heading “Threat Components” within the Firm’s Annual Data Kind dated June 30, 2022, a duplicate of which is accessible on Aequus’ profile on the SEDAR web site at www.sedar.com, and as in any other case disclosed on occasion on Aequus’ SEDAR profile. Ought to a number of of those dangers or uncertainties, or a threat that’s not at present identified to us materialize, or ought to assumptions underlying these forward-looking statements show incorrect, precise outcomes could range materially from these described herein. These forward-looking statements are made as of the date of this launch and we don’t intend, and don’t assume any obligation, to replace these forward-looking statements, besides as required by relevant securities legal guidelines. Buyers are cautioned that forward-looking statements usually are not ensures of future efficiency and are inherently unsure. Accordingly, traders are cautioned to not put undue reliance on ahead trying statements.
Neither the TSX Enterprise Change nor its Regulation Companies Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Change) accepts duty for the adequacy or accuracy of this information launch.
Contact Data:
Aequus Investor Relations
E-mail: traders@aequuspharma.ca
Cellphone: 604-336-7906
